Docs embrace Takeda’s Eohilia, creating competition for Sanofi, Regeneron’s blockbuster Dupixent
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s big blockbuster drug. The FDA rejected Eohilia, which Takeda called TAK-721 during development, in the chronic inflammatory disease eosinophilic esophagitis in […]
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic esophagitis (EoE) in patients aged 11 and older. This […]
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights. EXTON, PA., June 24, 2024 – The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns. DME is the leading cause […]
Spherix Global Insights Appoints Leigh Anne Siino as Chief Revenue Officer
Leigh Anne Siino joins executive team to accelerate company’s revenue growth. EXTON, PA., June 17, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is proud to announce the appointment of Leigh Anne Siino as Chief Revenue Officer (CRO). In this role, […]
Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s Saphnelo (anifrolumab) for SLE, […]
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Exton, PA., June 12, 2024 – Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative colitis (UC) […]
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME markets, according to Spherix Global Insights. EXTON, PA., May 1, 2024 — In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus […]
‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, […]
Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters new phase
Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to grow its U.S. field force by 30% as it works with Eisai on direct to patient and caregiver omnichannel marketing campaigns. The landmark Alzheimer’s disease drug ambled out of the gate after […]
Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S. were receiving the amyloid-busting antibody […]